PsiOxus lures two corporate VCs into £22m series B for oncolytic vaccine
This article was originally published in Scrip
Executive Summary
PsiOxus Therapeutics, a UK-based biotechnology company, has raised £22 million in a series B round in which existing investors Imperial Innovations and Invesco Perpetual each put in £5.5 million. The remaining £11 million was supplied by new investors SR One (GlaxoSmithKline's venture arm) and Lundbeckfond Ventures.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.